Circulating CD14++CD16+ Monocyte Subsets as a Surrogate Marker of the Therapeutic Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis

Makoto Orii; Toshio Imanishi; Ikuko Teraguchi; Tsuyoshi Nishiguchi; Yasutsugu Shiono; Takashi Yamano; Yasushi Ino; Kumiko Hirata; Takashi Kubo; Atsushi Tanaka; Takashi Akasaka

doi:10.1253/circj.CJ-14-1422

Myocardial Disease

Circulating CD14⁺⁺CD16⁺ Monocyte Subsets as a Surrogate Marker of the Therapeutic Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis

Makoto Orii, Toshio Imanishi, Ikuko Teraguchi, Tsuyoshi Nishiguchi, Yasutsugu Shiono, Takashi Yamano, Yasushi Ino, Kumiko Hirata, Takashi Kubo, Atsushi Tanaka, Takashi Akasaka

Author information

Makoto Orii
Department of Cardiovascular Medicine, Wakayama Medical University
Toshio Imanishi
Department of Cardiovascular Medicine, Wakayama Medical University
Ikuko Teraguchi
Department of Cardiovascular Medicine, Wakayama Medical University
Tsuyoshi Nishiguchi
Department of Cardiovascular Medicine, Wakayama Medical University
Yasutsugu Shiono
Department of Cardiovascular Medicine, Wakayama Medical University
Takashi Yamano
Department of Cardiovascular Medicine, Wakayama Medical University
Yasushi Ino
Department of Cardiovascular Medicine, Wakayama Medical University
Kumiko Hirata
Department of Cardiovascular Medicine, Wakayama Medical University
Takashi Kubo
Department of Cardiovascular Medicine, Wakayama Medical University
Atsushi Tanaka
Department of Cardiovascular Medicine, Wakayama Medical University
Takashi Akasaka
Department of Cardiovascular Medicine, Wakayama Medical University

Keywords: Cardiac sarcoidosis, CD14⁺⁺16⁺ monocytes, ¹⁸F-fluoro-2-deoxyglucose, Positron emission tomography

JOURNAL FREE ACCESS FULL-TEXT HTML

2015 Volume 79 Issue 7 Pages 1585-1592

DOI https://doi.org/10.1253/circj.CJ-14-1422

Editorial (79-7 pp. 1450-1452)

Browse “Advance online publication” version

Details

Abstract

Background:We aimed to evaluate whether specific monocyte subsets could serve as surrogate markers of disease activity in cardiac sarcoidosis (CS) evaluated by ¹⁸F-fluoro-2-deoxyglucose positron emission tomography (¹⁸F-FDG PET).Methods and Results:We studied 28 patients with CS (8 men; mean age: 61±9 years) diagnosed according to consensus criteria. We divided the patients into 2 groups: known CS receiving corticosteroid therapy (Rx(+); n=13) and new-onset CS (Rx(−); n=15), and analyzed 3 distinct monocyte subsets (CD14⁺CD16⁻, CD14⁺⁺CD16⁺, and CD14⁺⁻CD16⁺). Monocyte subsets were also analyzed in 10 Rx(−) patients before and 12 weeks after starting corticosteroid therapy. Inflammatory activity was quantified by ¹⁸F-FDG PET using the coefficient of variation (COV) of the standardized uptake value (SUV). The proportion of CD14⁺⁺CD16⁺monocytes in Rx(+) patients (10.8 [0.2–23.5] %) was significantly lower than in Rx(−) patients (23.0 [11.5–38.4] %, P=0.001). After corticosteroid therapy, the COV of the SUV was significantly improved from 0.32 [0.14–0.62] to 0.17 [0.04–0.43] (P=0.017). The proportion of CD14⁺⁺16⁺monocytes showed a significant decrease from 22.2 [8.8–38.4] % to 8.4 [1.8–16.8] % (P=0.001). The decrease in the proportion of CD14⁺⁺16⁺monocytes significantly correlated with the decrease in the COV of the SUV (r=0.495, P=0.027).Conclusions:CD14⁺⁺16⁺monocytes are a possible surrogate marker of the therapeutic effect of corticosteroid therapy in CS. (Circ J 2015; 79: 1585–1592)

Corresponding author

Register with J-STAGE for free!